{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:40:35Z","timestamp":1773286835946,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1016\/j.vaccine.2007.11.045","type":"journal-article","created":{"date-parts":[[2007,12,6]],"date-time":"2007-12-06T17:06:25Z","timestamp":1196960785000},"page":"664-676","source":"Crossref","is-referenced-by-count":43,"title":["Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: Intra-nasal vaccination"],"prefix":"10.1016","volume":"26","author":[{"given":"Sangeetha","family":"Vijaysri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garilyn","family":"Jentarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C.","family":"Heck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew A.","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin J.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertram L.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2007.11.045_bib1","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1073\/pnas.90.11.5214","article-title":"Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria","volume":"90","author":"Li","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2007.11.045_bib2","doi-asserted-by":"crossref","first-page":"7648","DOI":"10.1073\/pnas.95.13.7648","article-title":"Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine","volume":"95","author":"Sedegah","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2007.11.045_bib3","first-page":"51","article-title":"Viral vector systems for gene therapy","volume":"1","author":"Jolly","year":"1994","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.vaccine.2007.11.045_bib4","doi-asserted-by":"crossref","first-page":"11341","DOI":"10.1073\/pnas.93.21.11341","article-title":"Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety","volume":"93","author":"Moss","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2007.11.045_bib5","doi-asserted-by":"crossref","first-page":"11349","DOI":"10.1073\/pnas.93.21.11349","article-title":"Application of poxvirus vectors to vaccination: an update","volume":"93","author":"Paoletti","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2007.11.045_bib6","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/0042-6822(92)91246-Q","article-title":"Introduction of foreign DNA into vaccinia virus genome by direct ligation: recombination-independent selection cloning vectors","volume":"190","author":"Merchlinsky MaM","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2007.11.045_bib7","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1128\/JVI.70.4.2627-2631.1996","article-title":"Human cytotoxic T-cell memory: long-lived responses to vaccinia virus","volume":"70","author":"Demkowicz","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2007.11.045_bib8","first-page":"154","article-title":"Vaccinia virus in postvaccinal encephalitis","volume":"27","author":"Gurvich EBaV","year":"1983","journal-title":"Acta Virol"},{"key":"10.1016\/j.vaccine.2007.11.045_bib9","series-title":"Smallpox and its eradication","author":"Fenner","year":"1988"},{"key":"10.1016\/j.vaccine.2007.11.045_bib10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF01311044","article-title":"Vaccinia virus: a suitable vehicle for recombinant vaccines?","volume":"106","author":"Kaplan","year":"1989","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2007.11.045_bib11","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/aje\/kwh269","article-title":"Myopericarditis following smallpox vaccination","volume":"160","author":"Arness","year":"2004","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2007.11.045_bib12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacc.2004.05.004","article-title":"Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination","volume":"44","author":"Eckart","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vaccine.2007.11.045_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2458-3-1","article-title":"Risks of serious complications and death from smallpox vaccination: a systematic review of the United States experience, 1963\u20131968","volume":"3","author":"Aragon","year":"2003","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2007.11.045_bib14","first-page":"1","article-title":"Smallpox vaccination and adverse reactions. Guidance for clinicians","volume":"52","author":"Cono","year":"2003","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2007.11.045_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.virol.2005.06.043","article-title":"The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection","volume":"341","author":"Coulibaly","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2007.11.045_bib16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0042-6822(92)90752-B","article-title":"NYVAC: a highly attenuated strain of vaccinia virus","volume":"188","author":"Tartaglia","year":"1992","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2007.11.045_bib17","first-page":"125","article-title":"Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC","volume":"82","author":"Tartaglia","year":"1994","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2007.11.045_bib18","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1128\/JVI.74.2.923-933.2000","article-title":"Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine","volume":"74","author":"Ramirez","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2007.11.045_bib19","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/S0264-410X(00)00416-3","article-title":"Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the intravenous route in rhesus macaques","volume":"19","author":"Rosenwirth","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.11.045_bib20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.virol.2005.06.002","article-title":"Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model","volume":"339","author":"Meseda","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2007.11.045_bib21","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.vaccine.2005.11.022","article-title":"Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine","volume":"24","author":"Vollmar","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.11.045_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.1058915","article-title":"Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA\/MVA vaccine","volume":"292","author":"Amara","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2007.11.045_bib23","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1128\/JVI.75.2.850-856.2001","article-title":"Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model","volume":"75","author":"Brandt","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2007.11.045_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.virol.2005.01.006","article-title":"The N-terminal domain of the vaccinia virus E3L-protein is required for neurovirulence, but not induction of a protective immune response","volume":"333","author":"Brandt","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2007.11.045_bib25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1006\/viro.1994.1523","article-title":"Site-directed mutagenic analysis of reovirus sigma 3 protein binding to dsRNA","volume":"204","author":"Denzler","year":"1994","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2007.11.045_bib26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0042-6822(03)00433-1","article-title":"The Orf virus E3L homologue is able to complement deletion of the vaccinia virus E3L gene in vitro but not in vivo","volume":"314","author":"Vijaysri","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2007.11.045_bib27","series-title":"Generation of recombinant vaccinia viruses","author":"Earl","year":"1991"},{"key":"10.1016\/j.vaccine.2007.11.045_bib28","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1128\/JVI.67.6.3319-3325.1993","article-title":"Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene","volume":"67","author":"Blasco","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2007.11.045_bib29","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.vaccine.2003.10.022","article-title":"Mouse neurotoxicity test for vaccinia-based smallpox vaccines","volume":"22","author":"Li","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.11.045_bib30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/BF00370005","article-title":"Host-range restriction of vaccinia virus E3L-specific deletion mutants","volume":"12","author":"Beattie","year":"1996","journal-title":"Virus Genes"},{"key":"10.1016\/j.vaccine.2007.11.045_bib31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/viro.2002.1479","article-title":"The role of the PKR-inhibitory genes, E3L and K3L, in determining vaccinia virus host range","volume":"299","author":"Langland","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2007.11.045_bib32","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1006\/viro.1993.1292","article-title":"Identification of a conserved motif that is necessary for binding of the vaccinia virus E3L gene products to double stranded RNA","volume":"194","author":"Chang","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2007.11.045_bib33","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1128\/JVI.65.3.1530-1542.1991","article-title":"Identification and characterization of two nonessential regions of the rabbitpox virus genome involved in virulence","volume":"65","author":"Bloom","year":"1991","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2007.11.045_bib34","doi-asserted-by":"crossref","first-page":"10083","DOI":"10.1128\/JVI.00607-06","article-title":"Suppression of proinflammatory signal transduction and gene expression by the dual nucleic acid binding domains of the vaccinia virus E3L proteins","volume":"80","author":"Langland","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2007.11.045_bib35","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1016\/S0264-410X(00)00491-6","article-title":"Therapeutic vaccines against melanoma and colorectal cancer","volume":"19","author":"Tartaglia","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.11.045_bib36","series-title":"Poxvirus recombinants as live vaccines. Recombinant poxviruses","author":"Cox","year":"1992"},{"key":"10.1016\/j.vaccine.2007.11.045_bib37","doi-asserted-by":"crossref","first-page":"947","DOI":"10.20506\/rst.15.3.965","article-title":"Field use of a vaccinia-rabies recombinant vaccine for the control of sylvatic rabies in Europe and North America","volume":"15","author":"Brochier","year":"1996","journal-title":"Rev Sci Tech"},{"key":"10.1016\/j.vaccine.2007.11.045_bib38","first-page":"1632","article-title":"A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer","volume":"6","author":"Eder","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2007.11.045_bib39","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/S0264-410X(00)00488-6","article-title":"Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer","volume":"19","author":"Adams","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.11.045_bib40","first-page":"49","article-title":"Recombinant MUC 1 vaccinia virus: a potential vector for immunotherapy of breast cancer","volume":"40","author":"Balloul","year":"1994","journal-title":"Cell Mol Biol"},{"key":"10.1016\/j.vaccine.2007.11.045_bib41","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1089\/hum.1994.5.7-809","article-title":"In vivo delivery of interleukin-4 by a recombinant vaccinia virus prevents tumor development in mice","volume":"5","author":"Elkins","year":"1994","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2007.11.045_bib42","first-page":"59","article-title":"Construction of recombinant vaccinia virus expressing GM-CSF and its use as tumor vaccine","volume":"3","author":"Qin HXaC","year":"1996","journal-title":"Gene Ther"},{"key":"10.1016\/j.vaccine.2007.11.045_bib43","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S0264-410X(98)00324-7","article-title":"Mucosal and systemic immune responses induced after oral delivery of vaccinia virus recombinants","volume":"17","author":"Gherardi MMaE","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.11.045_bib44","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/978-1-4899-1828-4_60","article-title":"In defense of mucosal surfaces. Regulation and manipulation of the mucosal immune system","volume":"412","author":"Elson","year":"1997","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.vaccine.2007.11.045_bib45","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1006\/viro.1999.0001","article-title":"The complete DNA sequence of myxoma virus","volume":"264","author":"Cameron","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2007.11.045_bib46","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1006\/viro.2002.1446","article-title":"Analysis of the monkeypox virus genome","volume":"297","author":"Shchelkunov","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2007.11.045_bib47","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1006\/viro.1999.0002","article-title":"The complete genome sequence of shope (rabbit) fibroma virus","volume":"264","author":"Willer","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2007.11.045_bib48","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1099\/0022-1317-81-6-1439","article-title":"Long-term protective immunity to rinderpest in cattle following a single vaccination with a recombinant vaccinia virus expressing the virus haemagglutinin protein","volume":"81","author":"Ohishi","year":"2000","journal-title":"J Gen Virol."},{"key":"10.1016\/j.vaccine.2007.11.045_bib49","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1073\/pnas.96.8.4512","article-title":"Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity","volume":"96","author":"Belyakov","year":"1999","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07013485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07013485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T06:14:34Z","timestamp":1588140874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X07013485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0264410X07013485"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2007.11.045","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}